Case report · 30 Nov 2020
OtherPublished 23 Jul 2016
Dextromethorphan/quinidine for pseudobulbar affect
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Dextromethorphan/quinidine (DM/Q; NUEDEXTA) is approved by the US FDA for the treatment of pseudobulbar affect (PBA) associated with chronic neurological disorders such as multiple sclerosis, stroke, traumatic brain injury and amyotrophic lateral sclerosis. Studies of applications in other illnesses and for behavioral disinhibition are currently underway. The primary active agent is dextromethorphan, with quinidine added to inhibit its metabolism by CYP450 2D6 and increase the bioavailability of dextromethorphan. Published studies suggest reduction of episodes of PBA and improved quality of life with reasonable tolerability. However, the combination has the potential to interact with a number of other medications used by older patients. Some antidepressants may also be helpful in low doses for PBA and are easier to use, but more controlled studies with validated outcome measures are available for DM/Q. This article reviews published studies of DM/Q and addresses its use in clinical practice.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 4 Nov 2023
Characterization of poststroke psychiatric disorders including depression, anxiety, pseudobulbar affect, and apathy after cerebrovascular accident
Editorial · 30 Nov 2020
An Overview of Pseudobulbar Affect (PBA)
Conference abstract · 2 Oct 2017
Pseudobulbar affect, cognitive dysfunction and depression in poorly controlled diabetes
Rapid communication · 2015
Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment Options
More from this journal
The newest in Clinical Investigation.
Article · 30 Apr 2025
Vaccine Clinical Trials: Ensuring Safety, Immunity, and Public Health Protection
Article · 30 Apr 2025
Safety and Toxicity Assessment in Clinical Research: Ensuring Patient Protection and Drug Reliability
Article · 30 Apr 2025
Regulatory Compliance (FDA, EMA, CDSCO) in Drug Efficacy Studies: Ensuring Global Standards in Clinical Research
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Steven L Dubovsky”
